Erratum to: The AAPS Journal volume 22, Article number: 123 (2020)
10.1208/s12248-020-00508-2
The BCS classification for furosemide in Table 3 should read IV (not III).
Table III.
Summary of the Proposed Mechanism of Food Effect and the Associated Confidence Category in the PBPK Prediction of Food Effect. Color Coding Indicates Confidence in the PBPK Food Effect Prediction; Green: High; Yellow: Moderate; Red: Low
| Compound | Food Effect | BCS | Confidence in PBPK Prediction | Mechanism of Food Effect |
|---|---|---|---|---|
| Alectinib | Positive | II | Low | Changes in microenvironment pH and complex effect of formulation |
| Amiodarone | Positive | II | Low | Salt form |
| Aprepitant | Positive | II/IV | High (middle-out) | Bile acids and phospholipids |
| Cimetidine | None | III | High (middle-out) | No food effect |
| Clarithromycin | None | II | Moderate | No food effect |
| Dabrafenib | Negative | II | Low | Salt form; effect on microenvironment pH |
| Danazol | Positive | II | Low | Uncertainty in solubility (in vivo) |
| Danirixin | Negative | II | High (bottom-up) | Ion-pairing |
| d-Sotalol | None | III | High (middle-out) | No food effect |
| Etoricoxib | Negative | II | High (bottom-up) | GI motility changes in presence of food |
| Fluoxetine HCl | None | I | High (bottom-up) | No food effect |
| Furosemide | Negative | IV | High (bottom-up/middle-out) | GI motility changes in presence of food |
| Imatinib | None | II | High (middle-out) | No food effect |
| Isoniazid | Negative | I | Moderate | Drug-food interaction |
| Itraconazole | Positive | II | High (middle-out) | Buffer capacity alters dissolution |
| Ivacaftor | Positive | II/IV | High (middle-out) | Bile acids and phospholipids |
| Metoprolol | Positive | I | Moderate | Effect of hepatic and splanchnic blood flow |
| Nefazodone HCl | Negative | II | Moderate | Effect of hepatic and splanchnic blood flow |
| Nelfinavir Mesylate | Positive | II/IV | Moderate | Precipitation kinetics affected by food |
| Nifedipine | None | II | High (bottom-up) | No food effect |
| Oseltamivir | None | III | Moderate | No food effect |
| Panobinostat | None | II | High (bottom-up) | No food effect |
| Pazopanib | Positive | II/IV | Low | Impact of biorelevant buffer species on solubilization*; Salt form |
| Phenytoin | Positive | II | High (middle-out) | Bile acids and phospholipids |
| Telaprevir | Positive | II | Low | Impact of biorelevant buffer species on solubilization* |
| Tezacaftor | None | II | High (middle-out) | No food effect |
| Trospium IR/XR | Negative | III | Low | Changes in hydrodynamics (viscosity) in the presence of food |
| Venetoclax | Positive | IV | Moderate | Lymphatic uptake |
| Zidovudine | Negative | III | High (bottom-up) | GI motility changes in presence of food |
| Ziprasidone HCl | Positive | II | Moderate | Salt form |
*Specialized biorelevant media required to capture food effect
Footnotes
The online version of the original article can be found at 10.1208/s12248-020-00508-2
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.